Two FDA Device Authorisations, Two Sets of Evidence Narrower Than the Headline
- The FDA authorised Vitestro‘s Aletta on 19 August 2026 through the De Novo pathway, the first standalone robotic device that draws blood from a patient’s arm without hands-on operator intervention. It is cleared for adults in outpatient settings under a supervisor trained in phlebotomy, and one phlebotomist can oversee up to 3 devices at once.
- Aletta uses near-infrared light and Doppler ultrasound to locate a vein and distinguish it from an artery, then applies the tourniquet, prepares the skin, inserts and disposes of the needle, changes tubes and applies the bandage. FDA states success rates comparable to or better than trained phlebotomists when it proceeds with a stick. If no suitable vein is found, it declines.
- Separately, Maverix Medical announced 510(k) clearance (K261068) for the Narwhal Cryo System, a console-free single-use flexible cryoprobe for bronchoscopic cryobiopsy and palliative tissue devitalization. It delivers roughly 160 seconds of freeze endurance on a 1.3 mm shaft, with selectable 3 mm or 6 mm cryotip length.
- The Narwhal clearance was granted on 30 June 2026 and announced 51 days later, with broad US availability not expected until 2027. Support for the submission came from bench and animal testing. The clinical case cited is FROSTBITE-2 in JAMA, a 10% diagnostic yield lift, generated with a 1.1 mm cryoprobe.
CI read
Two authorisations, two different regulatory bars, one shared pattern. In each case the evidence supports a narrower claim than the announcement invites, and the gap sits in a subordinate clause rather than a footnote.
- Aletta’s comparability is conditional on the device agreeing to try. FDA’s wording is comparable or better when it proceeds with a stick. The device declines when it finds no suitable vein, and that decline rate appears nowhere in the 19 August authorisation. Ask Vitestro for yield per patient presented, not per attempt.
- The labour case is the actual product, and it is specific. One supervisor to 3 devices is the entire economic argument, and it only holds if declines are rare and reruns do not pull the phlebotomist back in. Model throughput on attempted draws per hour, including the ones the robot refuses.
- Narwhal borrows its clinical evidence from a different probe. The submission rested on bench and animal data. The 10% yield lift comes from FROSTBITE-2, run with a 1.1 mm cryoprobe, not the Narwhal. The quoted expert is a paid consultant. Console-free is a real workflow claim, and it is a separate claim from diagnostic yield.
Read the original source (FDA) → | Read the original source (Maverix Medical) →
GeographyUnited States